AAVXF

Healthcare Biotechnology

ABIVAX Société Anonyme

$139.00

+0.00 +0.00% today

Price History

Not enough data

Key Stats

Market Cap

12.13B

Avg Volume

EPS

-$6.08

52W High

$139.00

52W Low

$71.26

Div. Yield

0.0%

Valuation

P/B Ratio

26.91

P/S Ratio

2598.70

EV/EBITDA

-36.68

EV/Revenue

2290.79

Margins

Gross Margin 100.0%

Operating Margin (8617.9%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Revenue Growth (YoY)

(6.8%)

Return on Equity

(252.3%)

Return on Assets

(62.9%)

Liquidity & Leverage

Current Ratio

5.96

Quick Ratio

5.79

Debt / Equity

0.00

Total Cash

402.38M

Total Debt

1.21M

About

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.